

Mark Pimentel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2691286/mark-pimentel-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190
papers

8,364
citations

47
h-index

88
g-index

271
ext. papers

9,981
ext. citations

3.8
avg, IF

6.34
L-index

#	Paper	IF	Citations
190	Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk.. <i>Menopause</i> , 2022 , 29, 264-275	2.5	2
189	Smoking has disruptive effects on the small bowel luminal microbiome.. <i>Scientific Reports</i> , 2022 , 12, 62314	4.9	3
188	Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study. <i>Microorganisms</i> , 2022 , 10, 960	4.9	0
187	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021 , 116, 17-44	0.7	98
186	Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells via cell-cell signaling. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2021 , 226, 112357	6.7	
185	Quantitative sequencing clarifies the role of disruptor taxa, oral microbiota, and strict anaerobes in the human small-intestine microbiome. <i>Microbiome</i> , 2021 , 9, 214	16.6	5
184	High Prevalence of Small Intestinal Bacterial Overgrowth among Functional Dyspepsia Patients. <i>Digestive Diseases</i> , 2021 , 39, 382-390	3.2	7
183	Endotracheal Application of Ultraviolet-A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus-2: A First-in-Human Study. <i>Advances in Therapy</i> , 2021 , 38, 4556-4568	4.1	3
182	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. <i>Clinical Rheumatology</i> , 2021 , 40, 2277-2284	3.9	3
181	Irritable Bowel Syndrome in Pregnancy. <i>American Journal of Gastroenterology</i> , 2021 , 116, 480-490	0.7	2
180	Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	10
179	Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021 , 35, 102457	3.5	1
178	Age and the aging process significantly alter the small bowel microbiome. <i>Cell Reports</i> , 2021 , 36, 109765	10.6	9
177	Gut Microbiota Dysbiosis in Functional Dyspepsia. <i>Microorganisms</i> , 2020 , 8,	4.9	17
176	Acute appendicitis is associated with appendiceal microbiome changes including elevated levels. <i>BMJ Open Gastroenterology</i> , 2020 , 7,	3.9	4
175	Mapping the Segmental Microbiomes in the Human Small Bowel in Comparison with Stool: A REIMAGINE Study. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2595-2604	4	20
174	The duodenal microbiome is altered in small intestinal bacterial overgrowth. <i>PLoS ONE</i> , 2020 , 15, e0234906	3.6	23

173	Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. <i>Frontiers in Psychiatry</i> , 2020 , 11, 664	5	29
172	Comparing the rates of methane production in patients with and without appendectomy: results from a large-scale cohort. <i>Scientific Reports</i> , 2020 , 10, 867	4.9	4
171	ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. <i>American Journal of Gastroenterology</i> , 2020 , 115, 165-178	0.7	88
170	Microbiome and Its Role in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 829-839	4	42
169	Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00144	4.2	3
168	Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13875	4	5
167	Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2388-2396	4	2
166	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020 , 159, 1526-1532	13.3	33
165	Ultraviolet A light effectively reduces bacteria and viruses including coronavirus. <i>PLoS ONE</i> , 2020 , 15, e0236199	3.7	20
164	Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3115-3121	4	10
163	Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study. <i>BMC Microbiology</i> , 2019 , 19, 239	4.5	16
162	An Approach to the Patient With Chronic Undiagnosed Abdominal Pain. <i>American Journal of Gastroenterology</i> , 2019 , 114, 726-732	0.7	10
161	Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1886-1893	0.7	20
160	Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 182-188	4	1
159	Influence of Dietary Restriction on Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2019 , 114, 212-220	0.7	6
158	Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. <i>Gut Microbes</i> , 2019 , 10, 22-33	8.8	39
157	Dyssynergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1065-1073	4.5	16
156	Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1280-1290	4.5	21

155 Small Intestinal Bacterial Overgrowth **2018**, 333-342

154 Evidence-based management of irritable bowel syndrome with diarrhea. *American Journal of Managed Care*, **2018**, 24, S35-S46 2.1 16

153 Examination of the effects of breath hydrogen and methane levels on the EC/IR II. *Journal of the Canadian Society of Forensic Science*, **2017**, 50, 125-130 0.5

152 Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. *Digestive Diseases and Sciences*, **2017**, 62, 1480-1485 4 20

151 Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. *Digestive Diseases and Sciences*, **2017**, 62, 2455-2463 4 29

150 Measurement of Hydrogen Sulfide during Breath Testing Correlates to Patient Symptoms. *Gastroenterology*, **2017**, 152, S205-S206 13.3 3

149 Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation. *American Journal of Gastroenterology*, **2017**, 112, 656-657 0.7 1

148 Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. *American Journal of Gastroenterology*, **2017**, 112, 775-784 0.7 343

147 Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 689-699 4.7 8

146 Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. *Medical Hypotheses*, **2017**, 106, 26-32 3.8 16

145 Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, 5997-6001 5.9 10

144 Responders Analysis in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Rifaximin. *American Journal of Gastroenterology*, **2017**, 112, S236 0.7

143 Biomarkers of Irritable Bowel Syndrome. *Journal of Neurogastroenterology and Motility*, **2017**, 23, 20-26 4.4 29

142 Lactulose Breath Testing Predicts the Response to Rifaximin. *American Journal of Gastroenterology*, **2017**, 112, S227 0.7 1

141 Assessing the Efficacy of Rifaximin in Diarrhea-Predominant Irritable Syndrome (IBS-D): A Post hoc Analysis of 2 Phase 3, Randomized, Placebo-Controlled Trials. *American Journal of Gastroenterology*, **2017**, 112, S254 0.7

140 Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. *Gastroenterology*, **2016**, 151, 1113-1121 13.3 147

139 A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. *Clinical Therapeutics*, **2016**, 38, 1638-1652.e9 3.5 6

138 Autoimmunity and Irritable Bowel Syndrome: New Pathophysiology. *American Journal of Gastroenterology Supplements (Print)*, **2016**, 3, 41-45

137	Mo1641 Efficacy and Tolerability of Linaclotide and Plecanatide in Treating Irritable Bowel Syndrome With Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC): A Meta-Analysis. <i>Gastroenterology</i> , 2016 , 150, S739	13.3	15
136	Reply. <i>Gastroenterology</i> , 2016 , 150, 278-9	13.3	2
135	Understanding Breath Tests for Small Intestinal Bacterial Overgrowth. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1362-3	6.9	5
134	How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. <i>Current Gastroenterology Reports</i> , 2016 , 18, 8	5	83
133	Breath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?. <i>American Journal of Gastroenterology</i> , 2016 , 111, 307-8	0.7	18
132	Update on Irritable Bowel Syndrome Diagnostics and Therapeutics. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 442-5	0.7	
131	Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway. <i>F1000Research</i> , 2016 , 5, 606	3.6	14
130	Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. <i>Obesity</i> , 2016 , 24, 576-82	8	18
129	Abdominal Bloating and Visible Distension 2016 , 412-415		
128	Tu1804 Anti-Vinculin and Anti-CdtB Antibodies in Mexican Subjects: A Case Control Study. <i>Gastroenterology</i> , 2016 , 150, S952	13.3	2
127	Su1210 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients With IBS-C: Results of a Multi-Center Randomized Double-Blind Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2016 , 150, S496-S497	13.3	7
126	450 Hydrogen- and Methane- Based Breath Testing (BT) in Gastrointestinal (GI) Disorders: Report of the North American Consensus Meeting. <i>Gastroenterology</i> , 2016 , 150, S97	13.3	2
125	Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. <i>BMC Gastroenterology</i> , 2016 , 16, 67	3	31
124	Intestinal methane production is associated with decreased weight loss following bariatric surgery. <i>Obesity Research and Clinical Practice</i> , 2016 , 10, 728-733	5.4	8
123	Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43 Suppl 1, 37-49	6.1	48
122	Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following <i>Campylobacter jejuni</i> Infection in a Rat Model. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1195-205	4	51
121	Mo1865 Prevalence of Excessive Intestinal Methane Production and Its Variability With Age and Gender: A Large-Scale Database Analysis. <i>Gastroenterology</i> , 2015 , 148, S-729-S-730	13.3	3
120	Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 1076-87	2.4	65

119	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015 , 110, S761	0.7	2
118	Lovastatin Lactone Inhibits Methane Production in Human Stool Homogenates. <i>American Journal of Gastroenterology</i> , 2015 , 110, S753	0.7	6
117	Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. <i>PLoS ONE</i> , 2015 , 10, e0126438	3.7	83
116	The Prevalence of Irritable Bowel Syndrome in Patients With Typical Symptoms Referred to the Gastroenterologist: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2015 , 110, S758	0.7	2
115	Accurate Identification of Excessive Methane Gas Producers by a Single Fasting Measurement of Exhaled Methane: A Large-scale Database Analysis ACG Category Award. <i>American Journal of Gastroenterology</i> , 2015 , 110, S759-S760	0.7	7
114	Breath Testing for Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Metaanalysis. <i>American Journal of Gastroenterology</i> , 2015 , 110, S762-S763	0.7	5
113	Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. <i>Annals of Gastroenterology</i> , 2015 , 28, 87-93	2.2	6
112	Small Intestinal Bacterial Overgrowth 2015 , 125-136		1
111	In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 236-41	14.3	32
110	Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 973-83	6.1	11
109	Antibiotic treatment of constipation-predominant irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 1278-85	4	76
108	Methanogens, methane and gastrointestinal motility. <i>Journal of Neurogastroenterology and Motility</i> , 2014 , 20, 31-40	4.4	134
107	Placebo effect in clinical trial design for irritable bowel syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2014 , 20, 163-70	4.4	29
106	Gastroesophageal Reflux Reported on Esophagram Does Not Correlate with pH Monitoring and High-resolution Esophageal Manometry. <i>American Surgeon</i> , 2014 , 80, 1026-1029	0.8	3
105	Adverse events appear to unblind clinical trials in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2014 , 26, 482-8	4	18
104	Probiotics for antibiotic-associated diarrhea: PLACIDE swings the pendulum. <i>Gastroenterology</i> , 2014 , 146, 1822-3	13.3	4
103	Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. <i>BMC Gastroenterology</i> , 2013 , 13, 46	3	42
102	The effect of rifaximin on gut flora and Staphylococcus resistance. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 1676-82	4	29

101	Pathogen-specific risk of celiac disease following bacterial causes of foodborne illness: a retrospective cohort study. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3242-5	4	40
100	Tu2030 Quantitation of Bacteria in Duodenal Aspirates by qPCR Appears to Identify Viable Organisms in IBS. <i>Gastroenterology</i> , 2013 , 144, S-908	13.3	2
99	Tu2110 Circulating Antibodies to Cytolethal Distending Toxin B Correlate With the Development of Small Intestinal Bacterial Overgrowth in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2013 , 144, S-931-S-932	13.3	4
98	Gas and the microbiome. <i>Current Gastroenterology Reports</i> , 2013 , 15, 356	5	59
97	Tu2029 Deep Sequencing Reveals That the Microbiome of the Human Duodenum Is Unique and Unrelated to Stool Bacterial Profiling. <i>Gastroenterology</i> , 2013 , 144, S-908	13.3	2
96	Severity of dyspeptic symptoms correlates with delayed and early variables of gastric emptying. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 478-87	4	18
95	Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. <i>Therapeutic Advances in Chronic Disease</i> , 2013 , 4, 223-31	4.9	106
94	Measuring response in the gastrointestinal tract in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 700-6	5.3	41
93	Effect of repeated <i>Campylobacter jejuni</i> infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. <i>Neurogastroenterology and Motility</i> , 2013 , 25, 529-37	4	17
92	Intestinal <i>Methanobrevibacter smithii</i> but not total bacteria is related to diet-induced weight gain in rats. <i>Obesity</i> , 2013 , 21, 748-54	8	44
91	Recorded lower esophageal pressures as a function of electronic sleeve placement and location of gastric pressure measurement in patients with hiatal hernia. <i>Journal of Neurogastroenterology and Motility</i> , 2013 , 19, 479-84	4.4	
90	Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 505-11	0.7	9
89	<i>Methanobrevibacter smithii</i> is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 3213-8	4	100
88	Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literature. <i>European Journal of Medical Genetics</i> , 2012 , 55, 548-51	2.6	29
87	Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. <i>American Journal of Medicine</i> , 2012 , 125, 381-93	2.4	56
86	Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2012 , 12, 55	3	43
85	Antibiotics for irritable bowel syndrome: rationale and current evidence. <i>Current Gastroenterology Reports</i> , 2012 , 14, 439-45	5	32
84	Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012 , 18, 200-4	4.4	28

83	Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012 , 18, 434-442	4.4	34
82	The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 1321-9	4	131
81	Methanogens in Human Health and Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012 , 1, 28-33		58
80	"Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 686-90	3	13
79	Intestinal methane production in obese individuals is associated with a higher body mass index. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 22-8	0.7	29
78	Rifaximin therapy for patients with irritable bowel syndrome without constipation. <i>New England Journal of Medicine</i> , 2011 , 364, 22-32	59.2	690
77	Small Bowel Culture Confirms the Presence of Small Intestinal Bacterial Overgrowth in a Subset of IBS Subjects. <i>Gastroenterology</i> , 2011 , 140, S-152	13.3	3
76	Inflammation and microflora. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 69-85	4.4	23
75	Concomitant Methane and Hydrogen Production in Humans is Associated With a Higher Body Mass Index. <i>Gastroenterology</i> , 2011 , 140, S-335	13.3	3
74	Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 790-3	3	2
73	Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 40-4	3	9
72	History of tonsillectomy is associated with irritable bowel syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 912	3	11
71	Apple sauce improves detection of esophageal motor dysfunction during high-resolution manometry evaluation of dysphagia. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 1723-8	4	26
70	Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 1962-6	4	10
69	Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2059-66	4	11
68	Methane on breath testing is associated with constipation: a systematic review and meta-analysis. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 1612-8	4	113
67	Acute and chronic histological changes of the small bowel secondary to <i>C. jejuni</i> infection in a rat model for post-infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2575-84	4	22
66	Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2067-72	4	75

65	Serum sTREM-1 as a surrogate marker of treatment outcome in patients with peptic ulcer disease. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 3590-5	4	5
64	Antibiotics for the treatment of irritable bowel syndrome. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 455-93	0.7	23
63	Abdominal Bloating and Visible Distension 2010 , 161-168		
62	Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1. <i>American Journal of Gastroenterology</i> , 2010 , 105, 718-21	0.7	25
61	Lactose intolerance and the role of the lactose breath test. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1726-8	0.7	46
60	An evidence-based treatment algorithm for IBS based on a bacterial/SIBO hypothesis: Part 2. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1227-30	0.7	13
59	T2085 Methane on Breath Testing is Associated With Constipation: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2010 , 138, S-629	13.3	2
58	475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2). <i>Gastroenterology</i> , 2010 , 138, S-64-S-65	13.3	6
57	Irritable bowel syndrome and small intestinal bacterial overgrowth. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 672-5	3	29
56	A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 547-50	3	56
55	New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 145-9	4	24
54	Evaluating breath methane as a diagnostic test for constipation-predominant IBS. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 398-403	4	57
53	Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1085-9	4	22
52	Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2302-8	4	28
51	Methane and the gastrointestinal tract. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2135-43	4	143
50	Abnormal breath testing in IBS: a meta-analysis. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2441-9	4	119
49	Esophageal motor dysfunction and gastroesophageal reflux are prevalent in lung transplant candidates. <i>Annals of Thoracic Surgery</i> , 2010 , 90, 1630-6	2.7	35
48	Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. <i>Gender Medicine</i> , 2010 , 7, 240-6		25

47	The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-15	0.7	1
46	ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. <i>World Journal of Gastroenterology</i> , 2010 , 16, 3680-6	5.6	29
45	Review of rifaximin as treatment for SIBO and IBS. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 349-58	5.9	67
44	A high-resolution view of achalasia. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 644-51	3	13
43	Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. <i>Gastroenterology and Hepatology</i> , 2009 , 5, 435-42	0.7	11
42	New Onset Gastroesophageal Reflux Disease After Acute Gastroenteritis: A Case of Post-Infectious GERD?. <i>American Journal of Gastroenterology</i> , 2009 , 104, S367	0.7	
41	T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response. <i>Gastroenterology</i> , 2008 , 134, A-545	13.3	47
40	A systematic review of diagnostic tests for small intestinal bacterial overgrowth. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 1443-54	4	199
39	Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 169-74	4	97
38	A new rat model links two contemporary theories in irritable bowel syndrome. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 982-9	4	67
37	The degree of breath methane production in IBS correlates with the severity of constipation. <i>American Journal of Gastroenterology</i> , 2007 , 102, 837-41	0.7	137
36	Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do. <i>Current Treatment Options in Gastroenterology</i> , 2007 , 10, 328-37	2.5	20
35	Irritable bowel syndrome: Bacterial overgrowth--What's known and what to do. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007 , 10, 328-337	2.1	
34	Case studies of antibiotic therapy in the management of functional gastrointestinal disorders. <i>Gastroenterology and Hepatology</i> , 2007 , 3, 1-12	0.7	
33	Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. <i>Current Gastroenterology Reports</i> , 2006 , 8, 305-11	5	46
32	Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G1089-95	5.1	280
31	The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. <i>Annals of Internal Medicine</i> , 2006 , 145, 557-63	8	343
30	Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1297-301	4	116

29	Studying the overlap between IBS and GERD: a systematic review of the literature. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 2113-20	4	76
28	Gastrointestinal Infection with <i>Campylobacter jejuni</i> 81176 Produces Altered Bowel Function and Bacterial Overgrowth in Rats. <i>American Journal of Gastroenterology</i> , 2006 , 101, S472	0.7	3
27	Measurement of gastrointestinal transit. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 989-1004	4	131
26	Rifaximin, a Non-Absorbable Antibiotic, Improves the Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005 , 100, S324	0.7	10
25	Bacterial concepts in irritable bowel syndrome. <i>Reviews in Gastroenterological Disorders</i> , 2005 , 5 Suppl 3, S3-9		5
24	A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 450-2	2.4	94
23	A 14-day elemental diet is highly effective in normalizing the lactulose breath test. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 73-7	4	52
22	IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 84-7	4	41
21	Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2700-4	0.7	50
20	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2003 , 98, 412-9	0.7	502
19	THE PRESENCE OF CONSTIPATION AND METHANE ON LACTULOSE BREATH TEST IN IBS SUBJECTS IS ASSOCIATED WITH LOWER SEROTONIN LEVELS COMPARED TO HYDROGEN ALONE. <i>American Journal of Gastroenterology</i> , 2003 , 98, S72	0.7	65
18	Methane production during lactulose breath test is associated with gastrointestinal disease presentation. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 86-92	4	174
17	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2003 , 98, 412-419	0.7	11
16	Response to Dr. Parisi et al.. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2573-2574	0.7	3
15	Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 2639-43	4	114
14	Do antibiotics influence IBS?. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2681	0.7	5
13	Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux. <i>Journal of Clinical Gastroenterology</i> , 2002 , 34, 221-4	3	59
12	Postprandial improvement of gastric dysrhythmias in patients with type II diabetes: identification of responders and nonresponders. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 705-12	4	14

11	Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. <i>Archives of Internal Medicine</i> , 2001 , 161, 2081-8		52
10	Response to Dr. Riordan et al.. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2507-2508	0.7	1
9	Response to Drs. Mishkin. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2505-2506	0.7	
8	Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia. <i>Journal of Musculoskeletal Pain</i> , 2001 , 9, 105-113		10
7	Peppermint oil improves the manometric findings in diffuse esophageal spasm. <i>Journal of Clinical Gastroenterology</i> , 2001 , 33, 27-31	3	55
6	Identification of a prodromal period in Crohn's disease but not ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3458-62	0.7	102
5	Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3503-6	0.7	532
4	Aberrant TGF-beta production and regulation in metastatic malignancy. <i>Growth Factors</i> , 1990 , 3, 115-27	1.6	57
3	Intestinal Methanobrevibacter smithii but Not Total Bacteria Is Related to Diet-Induced Weight Gain in Rats. <i>Obesity</i> ,	8	2
2	Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells even at a distance from the light source		1
1	Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study		1